This is a procedural amendment that does not change the deal economics. Monitor for the definitive proxy statement filing, which will contain the shareholder vote date and management's recommendation. The merger remains subject to stockholder approval and regulatory clearances — any delay or opposition in the proxy process would be the next material catalyst.
Price Chart
Executive Summary
XOMA Royalty Corp filed a DEFA14A (definitive additional proxy soliciting material) disclosing Amendment No. 1 to its Agreement and Plan of Merger with Ligand Pharmaceuticals. The amendment adds XOMA Royalty Holdings Corporation (HoldCo) as a party to facilitate a holding company reorganization ahead of the merger, where Merger Sub will merge into HoldCo, leaving HoldCo as a wholly owned subsidiary of Ligand. This is a procedural step advancing the previously announced acquisition — no new financial terms or deal value were disclosed.
Key Facts
- Amendment No. 1 adds XOMA Royalty Holdings Corporation (HoldCo) as a party to the Merger Agreement dated April 27, 2026.
- HoldCo was formed on May 15, 2026, solely to effect a holding company reorganization under Nevada law.
- The merger structure: Flex Merger Sub will merge into HoldCo, with HoldCo surviving as a wholly owned subsidiary of Ligand Pharmaceuticals.
- No changes to deal consideration, conditions, or closing timeline were disclosed in this amendment.
- The filing is a DEFA14A — additional definitive proxy soliciting material related to the shareholder vote on the acquisition.
Financial Impact
No financial figures disclosed in this filing — deal value and consideration terms were not amended.
Risk Factors
- Stockholder vote on the merger may not pass — risk of deal failure.
- Regulatory approvals (HSR, foreign filings) could delay or block closing.
- HoldCo reorganization adds a structural layer — any complications in the reorganization could delay the merger timeline.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-228037 |
| Document: 0001193125-26-228037-index-headers.html | 0001193125-26-228037 |
| Document: 0001193125-26-228037-index.html | 0001193125-26-228037 |
| Document: 0001193125-26-228037.txt | 0001193125-26-228037 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 10, 2026 16w ago | DEFM14A | $25.51 $24.98 | ▼ −2.07% | ▼ −3.96% | — |
May 26, 2026 18w ago | 425 | $25.36 $25.48 | ▲ +0.47% | ▲ +2.42% | — |
May 18, 2026 19w ago | DEFA14A | $25.38 $25.40 | ▲ +0.08% | ▼ −1.50% | — |
Apr 27, 2026 22w ago | DEFA14A | $25.25 $25.36 | ▲ +0.44% | ▼ −4.52% | — |
Apr 27, 2026 22w ago | 8-K | $25.25 $25.36 | ▲ +0.44% | ▼ −4.52% | — |
Mar 30, 2026 26w ago | DEFA14A | $25.74 $25.62 | ▼ −0.47% | ▼ −9.89% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access